alexa Atomoxetine for the Treatment of Adults with Attention Deficit Hyperactivity Disorder: A Cost-Utility Analysis in Spain
ISSN 2472-1042

Pharmacoeconomics: Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Atomoxetine for the Treatment of Adults with Attention Deficit Hyperactivity Disorder: A Cost-Utility Analysis in Spain

Antje Tockhorn1, Foula Televantou1, Kristina Karlsdotter1 and Tatiana Dilla2*

1Eli Lilly and Company Limited, Windlesham, UK

2Lilly S.A., Alcobendas (Madrid), Spain

*Corresponding Author:
Tatiana Dilla
Eli Lilly Spain, Av. de la Industria
30, 28108 Alcobendas, Madrid, Spain
Tel: +343491663533
E-mail: [email protected]

Received date: November 21, 2015; Accepted date: December 21, 2015; Published date: December 28, 2015

Citation: Tockhorn A, Televantou F, Karlsdotter K, Dilla T (2015) Atomoxetine for the Treatment of Adults with Attention Deficit Hyperactivity Disorder: A Cost-Utility Analysis in Spain. Pharmacoeconomics 1:104. doi: 10.4172/2472-1042.1000104

Copyright: © 2015 Tockhorn A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: Attention-deficit hyperactivity disorder (ADHD) frequently persists into adulthood and leads to a significant burden of illness. Many adults with ADHD suffer from comorbid conditions such as substance and alcohol use disorders and anxiety. Atomoxetine is the only drug therapy approved in Spain for the treatment of adult ADHD. This study estimates the cost-utility of atomoxetine compared with no treatment in adults with ADHD in Spain and in two specific subgroups: patients with comorbid anxiety or comorbid alcohol abuse.
Method: A simple, state-transition Markov model with three health-states (treatment initiation, response and no-response) was developed. The model estimated the incremental cost per quality-adjusted life year (QALY). Treatment effectiveness and discontinuation rates were estimated from nine atomoxetine clinical trials. Utilities were estimated from a vignette study. Costs and outcomes were estimated over a one-year period from the perspective of the Spanish National Healthcare System.
Results: The incremental cost per QALY gained with atomoxetine versus no treatment was €23,645 in the general ADHD population, €20,860 in patients with comorbid anxiety, and €24,675 in the comorbid alcohol abuse population. These values were below the willingness-to-pay threshold of €30,000 per QALY considered acceptable in Spain. The model was most sensitive to changes in the utility value of patients in the no-response health state. With the exception of some of the utility values, a positive net monetary benefit value was maintained following variations in all model parameters.
Conclusion: Atomoxetine represents a cost-effective option compared

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords